Intersect ENT Inc. (NASDAQ:XENT) shares fell 1.9% during mid-day trading on Friday . The company traded as low as $15.24 and last traded at $15.51, with a volume of 77,820 shares trading hands. The stock had previously closed at $15.81.

A number of brokerages recently issued reports on XENT. Canaccord Genuity reissued a “buy” rating and set a $20.00 price target on shares of Intersect ENT in a research report on Thursday, August 4th. BTIG Research began coverage on shares of Intersect ENT in a research report on Tuesday, July 12th. They set a “neutral” rating for the company. Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Wednesday, May 11th. Wedbush reissued an “outperform” rating and set a $25.00 price target on shares of Intersect ENT in a research report on Wednesday, August 3rd. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $21.00 price target on shares of Intersect ENT in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $24.00.

The firm’s 50 day moving average price is $15.02 and its 200-day moving average price is $15.96. The stock’s market capitalization is $444.74 million.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.05. The firm had revenue of $19.30 million for the quarter, compared to the consensus estimate of $18.91 million. The company’s revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.23) EPS. Equities research analysts predict that Intersect ENT Inc. will post ($0.96) earnings per share for the current year.

In other news, VP James Stambaugh sold 3,977 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $17.00, for a total value of $67,609.00. Following the transaction, the vice president now directly owns 27,977 shares in the company, valued at $475,609. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.